|Articles|April 10, 2018
The Benefits of Jakafi for Patients With PV
Author(s)Jeanne M. Palmer, M.D.
Patients with PV tend to be very symptomatic, but Jakafi can help.
Advertisement
Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) — a type of myeloproliferative neoplasm.
Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us
5